Tuesday, November 21, 2006 8:00:00 AM PDT | VentureDeal Staff
MD -- TissueGene, an osteoarthritis therapy
biotechnology company, is close to finalizing an $18 million round of
financing, according to a Biz Journal report.
The company is close to beginning phase I clinical human trials of its genetic
therapy drug TG-C for osteoarthritis.
It is expected that the financing will assist the company in proceeding through
trial to commercialization. Total funding to date with the financing will
be $23 million.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
VentureDeal is a database that provides the latest information about venture capital, venture-backed technology companies, venture capital firms and transactions in the United States.
Learn More »
Deals & News
Email Sign Up
© 2013 VentureDeal, Inc., Menlo Park, CA. All Rights Reserved.